Several new medications are transforming diabetes care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as leading choices. Retatrutide, a double GIP and GLP-1 receptor activator, exhibits substantial body mass decrease along with improved glucose levels. Cagrillintide, another GLP-1 activator, is currently in clinical tri… Read More